

David Devos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3553147/publications.pdf>

Version: 2024-02-01

205
papers

11,142
citations

28190

55
h-index

38300

95
g-index

226
all docs

226
docs citations

226
times ranked

13144
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 195-210.	2.5	488
2	Colonic inflammation in Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 50, 42-48.	2.1	482
3	Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. <i>Neurobiology of Disease</i> , 2016, 94, 169-178.	2.1	472
4	The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 579-584.	0.9	396
5	STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. <i>Neurology</i> , 2008, 71, 80-84.	1.5	348
6	Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. <i>Free Radical Biology and Medicine</i> , 2019, 133, 221-233.	1.3	312
7	Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study. <i>Movement Disorders</i> , 2008, 23, 850-857.	2.2	231
8	Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. <i>Progress in Neurobiology</i> , 2021, 196, 101890.	2.8	220
9	Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 951-971.	1.9	199
10	Characteristics of apathy in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 778-784.	2.2	196
11	Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 993-1000.	2.2	172
12	Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the <i>TITF1/NKX2-1</i> gene. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 956-962.	0.9	172
13	Platelet microparticles: Detection and assessment of their paradoxical functional roles in disease and regenerative medicine. <i>Blood Reviews</i> , 2014, 28, 155-166.	2.8	161
14	Study of Circadian Melatonin Secretion Pattern at Different Stages of Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2003, 26, 65-72.	0.2	151
15	Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 589-596.	4.9	150
16	Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 668-674.	0.9	150
17	Elevated IL-6 and TNF- α levels in patients with ALS: Inflammation or hypoxia?. <i>Neurology</i> , 2005, 65, 1958-1960.	1.5	127
18	Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 470-475.	0.9	122

#	ARTICLE	IF	CITATIONS
19	1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2010, 5, e13223.	1.1	120
20	Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis. <i>Movement Disorders</i> , 2014, 29, 897-903.	2.2	120
21	Brief and sustained movements: differences in event-related (de)synchronization (ERD/ERS) patterns. <i>Clinical Neurophysiology</i> , 2000, 111, 2032-2039.	0.7	119
22	A specific clinical pattern of camptocormia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1229-1234.	0.9	116
23	Exhaustive, ONE-YEAR FOLLOW-UP OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION IN A LARGE, SINGLE-CENTER COHORT OF PARKINSONIAN PATIENTS. <i>Neurosurgery</i> , 2007, 61, 297-305.	0.6	114
24	Low levels of the vascular endothelial growth factor in CSF from early ALS patients. <i>Neurology</i> , 2004, 62, 2127-2129.	1.5	107
25	Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 90-95.	0.3	105
26	Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease. <i>Brain</i> , 2004, 127, 408-419.	3.7	104
27	Heart rate variability and Parkinson's disease severity. <i>Journal of Neural Transmission</i> , 2003, 110, 997-1011.	1.4	103
28	The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. <i>Neurology</i> , 2001, 57, 1359-1363.	1.5	101
29	<i>PRRT2</i> mutations. <i>Neurology</i> , 2012, 79, 170-174.	1.5	98
30	Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 407-421.	1.0	96
31	Iron as a therapeutic target for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 568-574.	2.2	94
32	A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. <i>Scientific Reports</i> , 2019, 9, 2918.	1.6	91
33	Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. <i>Brain</i> , 2008, 131, 1352-1361.	3.7	90
34	Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Caroline Moreau et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 742-748.	2.5	86
35	Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. <i>Neurobiology of Aging</i> , 2011, 32, 1839-1848.	1.5	83
36	Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. <i>BMC Neurology</i> , 2015, 15, 74.	0.8	83

#	ARTICLE	IF	CITATIONS
37	New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. <i>Movement Disorders</i> , 2006, 21, 2237-2240.	2.2	82
38	Clinical features and genetic analysis of a new form of spinocerebellar ataxia. <i>Neurology</i> , 2001, 56, 234-238.	1.5	81
39	Glycosphingolipids and neuroinflammation in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 59.	4.4	78
40	Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. <i>Journal of Proteome Research</i> , 2013, 12, 3746-3754.	1.8	77
41	Predominance of the contralateral movement-related activity in the subthalamo-cortical loop. <i>Clinical Neurophysiology</i> , 2006, 117, 2315-2327.	0.7	74
42	A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. <i>Annals of Neurology</i> , 2002, 52, 666-670.	2.8	73
43	Clinical syndromes: Parkinsonian gait. <i>Movement Disorders</i> , 2013, 28, 1552-1559.	2.2	73
44	Comparative analysis of targeted metabolomics: Dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. <i>Journal of Biomedical Informatics</i> , 2015, 53, 291-299.	2.5	73
45	Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. <i>Journal of Neural Transmission</i> , 2020, 127, 189-203.	1.4	71
46	Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?. <i>PLoS ONE</i> , 2016, 11, e0147947.	1.1	71
47	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 14.	2.5	70
48	Auditory cueing of gait initiation in Parkinson's disease patients with freezing of gait. <i>Clinical Neurophysiology</i> , 2014, 125, 1675-1681.	0.7	68
49	The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. <i>BMC Neurology</i> , 2016, 16, 155.	0.8	64
50	Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 173.	1.2	63
51	Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These?. <i>ACS Omega</i> , 2021, 6, 6528-6536.	1.6	63
52	Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 255-257.	0.9	61
53	STN-DBS FREQUENCY EFFECTS ON FREEZING OF GAIT IN ADVANCED PARKINSON DISEASE. <i>Neurology</i> , 2009, 72, 770-771.	1.5	61
54	Post translational changes to α -synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 45.	4.4	61

#	ARTICLE	IF	CITATIONS
55	Brain metabolic abnormalities during gait with freezing in Parkinson's disease. <i>Neuroscience</i> , 2015, 307, 281-301.	1.1	59
56	Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. <i>Movement Disorders</i> , 2008, 23, 2392-2397.	2.2	58
57	Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. <i>Brain</i> , 2009, 132, e109-e109.	3.7	58
58	Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates. <i>Journal of Neurology</i> , 2001, 248, 297-303.	1.8	57
59	ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. <i>Neurology</i> , 2005, 65, 1107-1110.	1.5	57
60	Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study. <i>Journal of Neurology</i> , 2016, 263, 1111-1119.	1.8	57
61	Factors Influencing Disease Progression in Autosomal Dominant Cerebellar Ataxia and Spastic Paraplegia. <i>Archives of Neurology</i> , 2012, 69, 500.	4.9	56
62	Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 552-555.	0.9	55
63	Early occurrence of inspiratory muscle weakness in Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0190400.	1.1	55
64	Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. <i>Journal of Neurology</i> , 2009, 256, 1736-1741.	1.8	54
65	The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study. <i>NeuroImage: Clinical</i> , 2019, 21, 101618.	1.4	54
66	Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0T magnetic resonance imaging study. <i>European Journal of Neurology</i> , 2014, 21, 1026-1031.	1.7	53
67	TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. <i>Brain</i> , 2014, 137, 2657-2663.	3.7	52
68	Iron Metabolism Disturbance in a French Cohort of ALS Patients. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	52
69	Ventilatory Dysfunction in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 463-471.	1.5	52
70	Amyloidogenic processing of Alzheimer's disease β -amyloid precursor protein induces cellular iron retention. <i>Molecular Psychiatry</i> , 2020, 25, 1958-1966.	4.1	52
71	Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. <i>Brain</i> , 2015, 138, 1271-1283.	3.7	51
72	Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 170-175.	1.1	50

#	ARTICLE	IF	CITATIONS
73	Deficit of sensorimotor integration in normal aging. <i>Neuroscience Letters</i> , 2011, 498, 208-212.	1.0	49
74	Regional siderosis: a new challenge for iron chelation therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 167.	1.6	48
75	The pattern of attentional deficits in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 300-305.	1.1	47
76	Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. <i>Journal of the Neurological Sciences</i> , 2014, 346, 85-89.	0.3	46
77	External Globus Pallidus Stimulation Modulates Brain Connectivity in Huntington's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 41-46.	2.4	45
78	Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. <i>Frontiers in Neurology</i> , 2019, 10, 835.	1.1	44
79	Psychosis, short stature in benign hereditary chorea: A novel thyroid transcription factor-1 mutation. <i>Movement Disorders</i> , 2008, 23, 1744-1747.	2.2	43
80	Untargeted ¹ H-NMR metabolomics in CSF. <i>Neurology</i> , 2014, 82, 1167-1174.	1.5	42
81	Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay. <i>Journal of Neurology</i> , 2015, 262, 2755-2763.	1.8	42
82	The Significance of Cortical Cerebellar Microbleeds and Microinfarcts in Neurodegenerative and Cerebrovascular Diseases. <i>Cerebrovascular Diseases</i> , 2015, 39, 138-143.	0.8	42
83	Differential susceptibility to the PPAR- γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. <i>Pharmacological Research</i> , 2012, 65, 514-522.	3.1	41
84	Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease. <i>Biomaterials</i> , 2017, 142, 77-89.	5.7	41
85	Methylphenidate. <i>CNS Drugs</i> , 2013, 27, 1-14.	2.7	40
86	Dyspnea: An underestimated symptom in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 162-166.	1.1	38
87	Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2016, 53, 6910-6924.	1.9	37
88	New Pharmacological Options for Treating Advanced Parkinson's Disease. <i>Clinical Therapeutics</i> , 2013, 35, 1640-1652.	1.1	36
89	The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 3236-3240.	1.3	35
90	Intravenous Thrombolysis for Acute Cerebral Ischaemia: Comparison of Outcomes between Patients Treated at Working versus Nonworking Hours. <i>Cerebrovascular Diseases</i> , 2010, 30, 148-156.	0.8	34

#	ARTICLE	IF	CITATIONS
91	Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 110-112.	1.1	34
92	Seven Solutions for Neuroprotection in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 306-316.	2.2	33
93	Effect of L-Dopa on the pattern of movement-related (de)synchronisation in advanced Parkinson's disease. <i>Neurophysiologie Clinique</i> , 2003, 33, 203-212.	1.0	32
94	Î±-Fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome. <i>Neurology</i> , 2003, 61, 268-269.	1.5	32
95	High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. <i>Neuromuscular Disorders</i> , 2007, 17, 169-173.	0.3	32
96	Deficient ðœsensoryð€beta synchronization in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2009, 120, 636-642.	0.7	31
97	Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. <i>Lancet Neurology</i> , The, 2022, 21, 428-437.	4.9	31
98	STN versus PPN-DBS for alleviating freezing of gait: Toward a frequency modulation approach?. <i>Movement Disorders</i> , 2009, 24, 2164-2166.	2.2	30
99	Deregulation of the hypoxia inducible factor-1Î± pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. <i>Neuroscience</i> , 2011, 172, 110-117.	1.1	30
100	Thickening of Peripapillar Retinal Fibers for the Diagnosis of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. <i>Cerebellum</i> , 2011, 10, 758-762.	1.4	30
101	Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study. <i>Movement Disorders</i> , 2016, 31, 1837-1845.	2.2	30
102	Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 56-62.	1.1	30
103	Perseveration for novel stimuli in Parkinson's disease: An evaluation based on event-related potentials topography. <i>Movement Disorders</i> , 2000, 15, 835-842.	2.2	29
104	Fluid-attenuated inversion recovery (FLAIR) sequences for the assessment of acute stroke. <i>Journal of Neurology</i> , 2006, 253, 631-635.	1.8	29
105	Effect of deep brain stimulation and L-Dopa on electrocortical rhythms related to movement in Parkinson's disease. <i>Progress in Brain Research</i> , 2006, 159, 331-349.	0.9	29
106	Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment. <i>Transfusion</i> , 2015, 55, 2433-2444.	0.8	29
107	Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 672-675.	1.8	28
108	Kjellin Syndrome: Long-term Neuro-ophthalmologic Follow-up and Novel Mutations in the SPG11 Gene. <i>Ophthalmology</i> , 2011, 118, 564-573.	2.5	28

#	ARTICLE	IF	CITATIONS
109	Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 194-201.	2.3	28
110	Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging of Lipids in Experimental Model of Traumatic Brain Injury Detecting Acylcarnitines as Injury Related Markers. <i>Analytical Chemistry</i> , 2019, 91, 11879-11887.	3.2	28
111	Motor preparation is more impaired in Parkinson's disease when sensorimotor integration is involved. <i>Clinical Neurophysiology</i> , 2003, 114, 2423-2433.	0.7	27
112	Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21). <i>Cerebellum</i> , 2008, 7, 179-183.	1.4	27
113	Guillain-Barré syndrome during childhood: Particular clinical and electrophysiological features. <i>Muscle and Nerve</i> , 2013, 48, 247-251.	1.0	26
114	Specific Attentional Disorders and Freezing of Gait in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 379-387.	1.5	26
115	Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: A review. <i>Revue Neurologique</i> , 2017, 173, 300-307.	0.6	26
116	Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. <i>Movement Disorders</i> , 2021, 36, 750-757.	2.2	26
117	Subthalamic stimulation influences postmovement cortical somatosensory processing in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2003, 18, 1884-1888.	1.2	25
118	CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 175-181.	2.3	25
119	Clinical features of amyotrophic lateral sclerosis and their prognostic value. <i>Revue Neurologique</i> , 2017, 173, 263-272.	0.6	25
120	Expanding the phenotype of SCA19/22: Parkinsonism, cognitive impairment and epilepsy. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 85-89.	1.1	25
121	Misdiagnoses in 1,250 Consecutive Patients Admitted to an Acute Stroke Unit. <i>Cerebrovascular Diseases</i> , 1997, 7, 284-288.	0.8	24
122	Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. <i>Movement Disorders</i> , 2011, 26, 534-538.	2.2	24
123	Gait and attentional performance in freezers under methylphenidate. <i>Gait and Posture</i> , 2015, 41, 384-388.	0.6	24
124	MRI of the cervical spinal cord predicts respiratory dysfunction in ALS. <i>Scientific Reports</i> , 2018, 8, 1828.	1.6	24
125	Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2022, 21, 225-233.	4.9	24
126	Mapping Spatiotemporal Microproteomics Landscape in Experimental Model of Traumatic Brain Injury Unveils a link to Parkinson's Disease*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1669-1682.	2.5	23

#	ARTICLE	IF	CITATIONS
127	Association of corticobasal degeneration and Huntington's disease: Can Tau aggregates protect Huntingtin toxicity?. <i>Movement Disorders</i> , 2009, 24, 1089-1090.	2.2	22
128	Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's disease. <i>European Journal of Neuroscience</i> , 2012, 36, 2669-2678.	1.2	22
129	Bioavailable Trace Metals in Neurological Diseases. <i>Current Treatment Options in Neurology</i> , 2016, 18, 46.	0.7	21
130	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. <i>Brain</i> , 2021, 144, 3142-3158.	3.7	21
131	Influence of internal globus pallidus stimulation on motor cortex activation pattern in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2002, 113, 1110-1120.	0.7	20
132	Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, 1154-1159.	1.8	20
133	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. <i>Journal of Biomedical Science</i> , 2019, 26, 89.	2.6	20
134	Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses. <i>Platelets</i> , 2021, 32, 259-272.	1.1	18
135	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. <i>Translational Neurodegeneration</i> , 2021, 10, 31.	3.6	18
136	Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. <i>Neurobiology of Disease</i> , 2017, 103, 24-31.	2.1	17
137	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. <i>Platelets</i> , 2021, 32, 226-237.	1.1	17
138	The role of the surface ligand on the performance of electrochemical SARS-CoV-2 antigen biosensors. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 103-113.	1.9	17
139	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 5823-5835.	2.6	17
140	4H syndrome: a rare cause of leukodystrophy. <i>Journal of Neurology</i> , 2010, 257, 1759-1761.	1.8	16
141	Spinocerebellar Ataxia: A Rational Approach to Aetiological Diagnosis. <i>Cerebellum</i> , 2012, 11, 289-299.	1.4	16
142	Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. <i>Acta Neurologica Belgica</i> , 2017, 117, 873-878.	0.5	16
143	SARS-CoV-2 detection using a nanobody-functionalized voltammetric device. <i>Communications Medicine</i> , 2022, 2, .	1.9	16
144	Pharmaceutical cognitive doping in students: A chimeric way to get-a-head?. <i>Therapie</i> , 2018, 73, 331-339.	0.6	15

#	ARTICLE	IF	CITATIONS
145	Are Upper-Body Axial Symptoms a Feature of Early Parkinson's Disease?. PLoS ONE, 2016, 11, e0162904.	1.1	15
146	RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease. Neurobiology of Disease, 2016, 96, 312-322.	2.1	14
147	Attenuated presentation of ataxia-telangiectasia with familial cancer history. Journal of Neurology, 2008, 255, 1261-1263.	1.8	12
148	Peripheral Autonomic Nervous System Involvement in Gaucher-Related Parkinsonism. Journal of Parkinson's Disease, 2014, 4, 29-32.	1.5	12
149	New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Movement Disorders, 2017, 32, 1365-1370.	2.2	12
150	Dyspnea Is a Specific Symptom in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 785-791.	1.5	12
151	Deciphering the natural history of SCA7 in children. European Journal of Neurology, 2020, 27, 2267-2276.	1.7	12
152	Early dopasensitive Parkinsonism related to myotonic dystrophy type 2. Movement Disorders, 2008, 23, 2100-2101.	2.2	11
153	Freezing of Swallowing. Movement Disorders Clinical Practice, 2016, 3, 490-493.	0.8	11
154	Opicapone for motor fluctuations in Parkinson's disease. Lancet Neurology, The, 2016, 15, 127-128.	4.9	11
155	Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study. Revue Neurologique, 2020, 176, 268-276.	0.6	11
156	Progressive MRI abnormalities in late recurrence of Sydenham's chorea. Journal of Neurology, 2005, 252, 1341-1344.	1.8	10
157	Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease. Scientific Reports, 2021, 11, 2724.	1.6	10
158	Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials, 2022, 280, 121311.	5.7	9
159	Abnormal cortical mechanisms in voluntary muscle relaxation in de novo parkinsonian patients. Journal of Clinical Neurophysiology, 2005, 22, 192-203.	0.9	9
160	Predictive Factors for Improvement of Gait by Low-Frequency Stimulation in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 413-420.	1.5	8
161	Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Neurobiology of Disease, 2020, 139, 104846.	2.1	8
162	Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease. International Immunopharmacology, 2021, 95, 107526.	1.7	8

#	ARTICLE	IF	CITATIONS
163	Limbic Stimulation Drives Mania in <scp>STNâ€DBS</scp> in Parkinson Disease: A Prospective Study. <i>Annals of Neurology</i> , 2022, 92, 411-417.	2.8	8
164	Sensing of COVID-19 spike protein in nasopharyngeal samples using a portable surface plasmon resonance diagnostic system. <i>Sensors & Diagnostics</i> , 2022, 1, 1021-1031.	1.9	8
165	Acetylcholinesterase inhibitors and gait: a steadying hand?. <i>Lancet Neurology</i> , The, 2016, 15, 232-233.	4.9	7
166	Segregation of ATP10B variants in families with autosomal recessive parkinsonism. <i>Acta Neuropathologica</i> , 2020, 140, 783-785.	3.9	7
167	Do kinematic gait parameters help to discriminate between fallers and non-fallers with Parkinsonâ€™s disease?. <i>Clinical Neurophysiology</i> , 2021, 132, 536-541.	0.7	7
168	Parkinsonâ€™s disease: Content analysis of patient online discussion forums. A prospective observational study using Netnography. <i>Patient Education and Counseling</i> , 2021, 104, 2060-2066.	1.0	6
169	Is <scp>TNF</scp> inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 689-694.	1.0	5
170	Personality dimensions of patients can change during the course of parkinsonâ€™s disease. <i>PLoS ONE</i> , 2021, 16, e0245142.	1.1	5
171	A Computational Exploration of the Molecular Network Associated to Neuroinflammation in Alzheimerâ€™s Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 630003.	1.6	5
172	Intracerebroventricular dopamine for Parkinson's disease. <i>Oncotarget</i> , 2017, 8, 45034-45035.	0.8	5
173	Neuroprotective activity of a virusâ€safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	5
174	A novel FTL insertion causing neuroferritinopathy. <i>Journal of Medical Genetics</i> , 2010, 47, 71-72.	1.5	4
175	Virtually reducing fall risk in Parkinson disease. <i>Neurology</i> , 2017, 89, 1762-1763.	1.5	4
176	Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinsonâ€™s Disease Patients (PSYCHO-STIM). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1-9.	1.5	4
177	Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study. <i>Clinical Neurophysiology</i> , 2021, 132, 2551-2557.	0.7	4
178	Clinical implications of neuropharmacogenetics. <i>Revue Neurologique</i> , 2015, 171, 482-497.	0.6	3
179	Efficacy of tDCS for bipolar depression in a patient with spinocerebellar ataxia: A case report. <i>Bipolar Disorders</i> , 2020, 22, 422-424.	1.1	3
180	Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinsonâ€™s Disease (PSYCHO-STIM II). <i>Journal of Parkinson's Disease</i> , 2022, 12, 699-711.	1.5	3

#	ARTICLE	IF	CITATIONS
181	Les nouvelles voies de recherche thérapeutique dans la sclérose latérale amyotrophique (SLA). <i>Pratique Neurologique - FMC</i> , 2016, 7, 9-15.	0.1	2
182	Trends in Glucocerebrosides Research: A Systematic Review. <i>Frontiers in Physiology</i> , 2020, 11, 558090.	1.3	2
183	Iron Chelation For Diseases Of Regional Siderosis. <i>Blood</i> , 2013, 122, 3435-3435.	0.6	2
184	Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. <i>Neurology</i> , 2021, 97, e1994-e2006.	1.5	2
185	Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2022, , .	1.1	2
186	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. <i>Biomolecules</i> , 2022, 12, 901.	1.8	2
187	Genetic characterization of cognitive impairment in Parkinson's disease. <i>Brain</i> , 2014, 137, 2630-2631.	3.7	1
188	Comment prendre en charge un malade atteint de SLA? <i>Pratique Neurologique - FMC</i> , 2015, 6, 13-18.	0.1	1
189	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. <i>Frontiers in Neurology</i> , 2019, 10, 833.	1.1	1
190	Functional correlates of cognitive slowing in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 3-9.	1.1	1
191	Neurological Phenotypes Associated with AAAS-Related Disorders: Spastic Ataxia and Complex Spastic Paraplegia. <i>Cerebellum</i> , 2020, 19, 465-468.	1.4	1
192	Joint latent class model: Simulation study of model properties and application to amyotrophic lateral sclerosis disease. <i>BMC Medical Research Methodology</i> , 2021, 21, 198.	1.4	1
193	Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder. <i>Movement Disorders</i> , 2022, , .	2.2	1
194	Levodopa for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 360, 935-936.	13.9	0
195	Comment gérer un traitement par Duodopa® dans la maladie de Parkinson à voluée? <i>Pratique Neurologique - FMC</i> , 2013, 4, 22-27.	0.1	0
196	PSP, pas vraiment. <i>Pratique Neurologique - FMC</i> , 2014, 5, 72-74.	0.1	0
197	Administration continue circadienne intra-cébro-ventriculaire de dopamine: un nouveau traitement de la maladie de Parkinson? Résultats chez l'animal. <i>Pratique Neurologique - FMC</i> , 2019, 10, 61-66.	0.1	0
198	Nouvelle stratégie de neuroprotection basée sur la chélation conservatrice du fer dans la maladie de Parkinson. <i>Pratique Neurologique - FMC</i> , 2019, 10, 44-54.	0.1	0

#	ARTICLE	IF	CITATIONS
199	Parkinson's disease: Improving person-centered care coordination by interdisciplinary communication and teamwork with patients: A qualitative mixed method study. <i>International Journal of Healthcare Management</i> , 0, , 1-8.	1.2	0
200	TNFalpha inhibitors and amyotrophic lateral sclerosis: a risk factor ?. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-12-19.	0.0	0
201	Discussion suite à la communication: «Nouvelle stratégie de neuroprotection basée sur la chélation conservatrice du fer dans la maladie de Parkinson». <i>Bulletin De L'Academie Nationale De Medecine</i> , 2019, 203, 440-441.	0.0	0
202	Intracerebroventricular administration of dopamine in Parkinson's disease: treatment of motor fluctuations and dyskinesia. , 2020, , 511-526.		0
203	Amyotrophic lateral sclerosis associated with a pathological expansion in the <i>ATXN7</i> gene. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, , 1-3.	1.1	0
204	Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21). <i>Cerebellum</i> , 2008, 7, 1-5.	1.4	0
205	Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. <i>Journal of Parkinson's Disease</i> , 2022, , 1-20.	1.5	0